If you do the, actual tax math and I know this is difficult, you'll discover that the tax liability is significantly covered and well-beyond. In addition, these were options as in they had the option to hold, even partially, and sold out. In the case of the VP of HR a total liquidation. Also, they had August 2014 buy options all in various ranges of the $5pps according to the SEC 4 forms of which none were activated by the MNKD officers. You are displaying cognitive dissonance toward new information, insider selling, that is counter to your investment thesis.
Viagra patent expires 2016. PFE has publicly ostracized both Exhubera and the technosphere. In addition, ANY new indication would require full FDA PDUFA and clinical testing. Years of work. Mitsubishi/Vivus/Auxiliuem have a 9/15/2014 FDA PDUFA label expansion for Stendra to expand the label to 15 minute fast action. Same BP biotechnology as Viagra but focused on genitalia. Like a laser beam versus a flood light. The 15 minute fast action ED Stendra is available for RX already and is having a solid drug launch. By 2016 generics and better biotechnology will render Viagra market share heavily diminished. Thank you for the genius compliment even if sarcastic. Good luck out there, you'll clearly need it.
Combine that with the expiring lockup Q4 2014. The gpro officers are up tremendously from the IPO on their stock options. Many have limited salaries and this is their yearly compensation. So, Gpro will follow up a realistic Q3 report (most likely in line with the previous 3 quarters) with a large amount of insider selling while being currently over-bought on emotional retail euphoria. I still love my Hero3. Happy trading.
I've shorted Gpro twice, highly successfully, and I bought a Hero3 with some of my profit from the last short. I am writing an article on how you can love a product but hate the stock and thought this would be a great way to demonstrate that point. Coincidentally, I also own a Sony HDR-HS20 and prefer it. I would advise any gpro investor to experience the different cameras available in this market. Currently, I have no position but I am considering a gpro short going into Q3 reporting.
*Facepalm. PFE had exhubera. There is no company is the world that loathes the technosphere more than Pfizer. Due diligence.
MNKD opened the year @ $5.20pps and is trading @ $7.40pps going into "profit-taking" season with no clear catalysts. Institutions, like MNKD officers, are taking profits (see SEC 4 filings). A reload will not occur until, at minimum, color is provided on the sales launch. No meaningful leg ups will occur without sales traction.
Insurance coverage has not been released. So about no providers have released any information at all. There was a survey done in January by MNKD and it did not show a positive favor-ability towards tier 2 coverage.
If you were able to accurately predict the ebb and flow would you have held all the way down from $10pps? Seems to me like you do not understand this stock. If you think I am swimming against the current I know you do not. Short interest just increased and the institutional report has not been released but like the MNKD officers I expect some sales occurred.
Those are in the SEC 4 filing from 8/26. They have additional August 2014 buy options in the $5pps range (changes from officer to officer) These options would need to be held for a predetermined period of time and none of them were activated.
EVERY single insider share was $0.00. EVERY SINGLE ONE. Not a single buy option was activated and they were all in the $5pps range.
I get them directly messaged. ALL the adds are at $0.00 pps, as compensation, and there are multiple insider sales. These SEC 4 filings reaffirm my point tremendously.
Correct Sanofi is unsure of insurance coverage. That is why they did not release it or even make a statement. Insurance coverage is outside of their control. The precedence set with Exhubera was absolutely zero coverage. That is the starting point that Sanofi must work from.
They can not sell immediately. Their employment/options contracts dictate they must hold for a certain amount of time.
Translation: None of the officers believe purchasing MNKD stock in August 2014 for $5pps range is a good investment.
VP of HR's sales were not pre-planned nor many of the other officers or attorney sales. If they believed there would be a rally why did NONE of them buy their August options in the $5pps range?
Don't forget about all the MNKD insider selling. Including the VP of HR total liquidation this month. Also, none of the options were exercised this month. Clearly, the officers at MNKD do not share the same belief as the retail longs.